Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

There are benefits and drawbacks to each type of treatment, but together you and your healthcare provider will decide what is ...

Nasal polyps are noncancerous growths that can form in the nasal cavity. Although benign, they can have a significant impact on a person’s quality of life. Nasal polyps often occur along with ...

Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic inflammation. While these benign growths themselves are not harmful ...

It’s this inflammation of the lining of your nose that produces the telltale stuffiness sensation of chronic nasal congestion ...

A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

The study's co-primary endpoints were to see the change from baseline in total endoscopic nasal polyp score at 52 weeks and the change from baseline in mean nasal obstruction score from weeks 49 ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

IL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play ... The only question is “Will you get into the right stocks early when their growth potential is greatest?” ...